Mtor inhibitor drugs

Drugs are classified according to the BC Cancer Drug Manual - nib = kinase inhibitors. - olimus = MTOR inhibitor. Target Listing.

The use of mTOR inhibitors may cause drug-induced pneumonitis, which usually responds well to steroids and withdrawal of the mTOR inhibitor. In cases of dyspnea during treatment, other causes should be excluded. The immunosuppressive activities of mTOR inhibitors are rare, but infections should be treated according to standard of care.

Immunosuppressant drug classes include calcineurin inhibitors, corticosteroids, antimetabolites, mTor inhibitors, and other immunosuppressants.

Drugs known as mTOR inhibitors have been included in ongoing and in recently completed cancer trials. New insights into the mTOR signaling system are helping to

Sunitinib, pazopanib, cabozantinib, axitinib, sorafenib, lenvatinib, and tivozanib are VEGF inhibitors. mTOR inhibitors: mTOR is a protein that

mTOR inhibitors are a class of drugs that inhibit the mechanistic target of rapamycin (mTOR), a serine/threonine-specific protein kinase.

Existing mTOR inhibitors are commonly divided into mTOR allosteric inhibitors, ATP-competitive inhibitors and dual binding site inhibitors, according to their sites of action. In addition, there exist several dual-target mTOR inhibitors that target PI3K, histone deacetylases (HDAC) or ataxia telangiectasia mutated and Rad-3 related (ATR) kinases.

Everolimus belongs to a class of drugs known as mTOR inhibitors, targeting the mTOR proteins that help cancer cells grow and divide. It can be used in post-

Moreover, dual PI3K/mTOR inhibitors have a reduced possibility to induce drug resistance than rapalogs, and mTOR kinase inhibitors can suppress mTORC1 and mTORC2 simultaneously; thus, these drugs are introduced as the second generation of mTOR inhibitor drugs in preclinical and clinical trials .